Bristol Myers: approval in lung cancer

(CercleFinance.com) - Bristol Myers Squibb reports that the FDA has approved the perioperative treatment of neoadjuvant Opdivo and chemotherapy, followed by surgery and a single adjuvant agent Opdivo, for resectable non-small cell lung cancer.


This US approval is based on the CheckMate-77T trial, which demonstrated significantly longer event-free survival compared to the chemotherapy and placebo arm, with a high rate of pathological complete response also observed.

This important milestone adds to Bristol Myers Squibb's thoracic portfolio and underscores the company's commitment to advancing treatments for patients with early-stage disease, the pharmaceutical company says.


Copyright (c) 2024 CercleFinance.com. All rights reserved.